Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Jay Parrish Biography and Net Worth

Insider of Vir Biotechnology

Jay Parrish, Ph.D., has served as our Chief Business Officer since July 2017 and is one of our co-founders. Prior to that, Dr. Parrish served as our Senior Vice President, Strategy and Corporate Development, from April 2017 to July 2017. Dr. Parrish is a Venture Partner at ARCH Venture Partners where he has served since May 2016. From September 2011 to May 2016, Dr. Parrish served in Gilead Sciences, Inc.’s Corporate Development group, where he was involved in building Gilead’s oncology and infectious disease portfolio, ultimately leading infectious disease business development for the company. Dr. Parrish also served as a scientist in Gilead’s medicinal chemistry group, from March 2004 to September 2011. Since 2012, Dr. Parrish has served as a part-time instructor at UC Berkeley Extension, where he teaches chemistry to undergraduates and post-baccalaureates. He also previously completed a postdoctoral fellowship at the Scripps Research Institute. Dr. Parrish received his B.S. in Chemistry from Emory University, a Ph.D. in Synthetic Organic Chemistry from the University of South Florida and an M.B.A. from the University of California, Berkeley Haas School of Business.

What is Jay Parrish's net worth?: The estimated net worth of Jay Parrish is at least $1.71 million as of February 1st, 2021. Dr. Parrish owns 224,536 shares of Vir Biotechnology stock worth more than $1,713,210 as of April 26th. This net worth estimate does not reflect any other investments that Dr. Parrish may own. Learn More about Jay Parrish's net worth.
How do I contact Jay Parrish?: The corporate mailing address for Dr. Parrish and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Jay Parrish's contact information.
Has Jay Parrish been buying or selling shares of Vir Biotechnology?: Jay Parrish has not been actively trading shares of Vir Biotechnology during the past quarter. Most recently, Jay Parrish sold 6,944 shares of the business's stock in a transaction on Monday, February 1st. The shares were sold at an average price of $69.91, for a transaction totalling $485,455.04. Following the completion of the sale, the insider now directly owns 224,536 shares of the company's stock, valued at $15,697,311.76. Learn More on Jay Parrish's trading history.
Who are Vir Biotechnology's active insiders?: Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?: In the last twelve months, insiders at the sold shares 26 times. They sold a total of 775,857 shares worth more than $17,733,362.17. The most recent insider tranaction occured on April, 3rd when CEO Backer Marianne De sold 72,995 shares worth more than $690,532.70. Insiders at Vir Biotechnology own 18.1% of the company. Learn More about insider trades at Vir Biotechnology.
Information on this page was last updated on 4/3/2024.

Jay Parrish Insider Trading History at Vir Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/1/2021	Sell	6,944	$69.91	$485,455.04	224,536
12/1/2020	Sell	6,945	$31.53	$218,975.85	226,852
11/2/2020	Sell	6,944	$31.27	$217,138.88	226,851
10/1/2020	Sell	6,945	$34.75	$241,338.75	226,852
8/3/2020	Sell	11,110	$47.65	$529,391.50
7/1/2020	Sell	75,000	$37.95	$2,846,250.00	248,147
6/1/2020	Sell	75,000	$35.22	$2,641,500.00	297,222
5/14/2020	Sell	75,000	$30.05	$2,253,750.00	297,222

Jay Parrish Buying and Selling Activity at Vir Biotechnology

Vir Biotechnology Company Overview

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Today's Range

Now: $7.63

$7.61

$8.00

50 Day Range

MA: $9.98

$7.63

$11.90

2 Week Range

Now: $7.63

$7.61

$27.48

Volume

901,238 shs

Average Volume

1,037,967 shs

Market Capitalization

$1.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.41

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad